144 related articles for article (PubMed ID: 20354505)
1. Regulation of retinal function but nonrescue of vision in RPE65-deficient dogs treated with doxycycline-regulatable AAV vectors.
Lhériteau E; Libeau L; Mendes-Madeira A; Deschamps JY; Weber M; Le Meur G; Provost N; Guihal C; Moullier P; Rolling F
Mol Ther; 2010 Jun; 18(6):1085-93. PubMed ID: 20354505
[TBL] [Abstract][Full Text] [Related]
2. Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
Rolling F; Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
Bull Mem Acad R Med Belg; 2006; 161(10-12):497-508; discussion 508-9. PubMed ID: 17503728
[TBL] [Abstract][Full Text] [Related]
3. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors.
Stieger K; Le Meur G; Lasne F; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Martin L; Moullier P; Rolling F
Mol Ther; 2006 May; 13(5):967-75. PubMed ID: 16442848
[TBL] [Abstract][Full Text] [Related]
4. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
Gene Ther; 2007 Feb; 14(4):292-303. PubMed ID: 17024105
[TBL] [Abstract][Full Text] [Related]
5. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog.
Narfström K; Katz ML; Bragadottir R; Seeliger M; Boulanger A; Redmond TM; Caro L; Lai CM; Rakoczy PE
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1663-72. PubMed ID: 12657607
[TBL] [Abstract][Full Text] [Related]
6. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.
Acland GM; Aguirre GD; Bennett J; Aleman TS; Cideciyan AV; Bennicelli J; Dejneka NS; Pearce-Kelling SE; Maguire AM; Palczewski K; Hauswirth WW; Jacobson SG
Mol Ther; 2005 Dec; 12(6):1072-82. PubMed ID: 16226919
[TBL] [Abstract][Full Text] [Related]
7. Successful gene therapy in older Rpe65-deficient dogs following subretinal injection of an adeno-associated vector expressing RPE65.
Annear MJ; Mowat FM; Bartoe JT; Querubin J; Azam SA; Basche M; Curran PG; Smith AJ; Bainbridge JW; Ali RR; Petersen-Jones SM
Hum Gene Ther; 2013 Oct; 24(10):883-93. PubMed ID: 24028205
[TBL] [Abstract][Full Text] [Related]
8. Gene transfer in the RPE65 null mutation dog: relationship between construct volume, visual behavior and electroretinographic (ERG) results.
Ford M; Bragadóttir R; Rakoczy PE; Narfström K
Doc Ophthalmol; 2003 Jul; 107(1):79-86. PubMed ID: 12906125
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function.
Annear MJ; Bartoe JT; Barker SE; Smith AJ; Curran PG; Bainbridge JW; Ali RR; Petersen-Jones SM
Gene Ther; 2011 Jan; 18(1):53-61. PubMed ID: 20703309
[TBL] [Abstract][Full Text] [Related]
10. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus.
Favre D; Blouin V; Provost N; Spisek R; Porrot F; Bohl D; Marmé F; Chérel Y; Salvetti A; Hurtrel B; Heard JM; Rivière Y; Moullier P
J Virol; 2002 Nov; 76(22):11605-11. PubMed ID: 12388721
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis.
Bemelmans AP; Kostic C; Crippa SV; Hauswirth WW; Lem J; Munier FL; Seeliger MW; Wenzel A; Arsenijevic Y
PLoS Med; 2006 Oct; 3(10):e347. PubMed ID: 17032058
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.
Li W; Kong F; Li X; Dai X; Liu X; Zheng Q; Wu R; Zhou X; Lü F; Chang B; Li Q; Hauswirth WW; Qu J; Pang JJ
Mol Vis; 2009; 15():267-75. PubMed ID: 19190735
[TBL] [Abstract][Full Text] [Related]
13. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.
Bennicelli J; Wright JF; Komaromy A; Jacobs JB; Hauck B; Zelenaia O; Mingozzi F; Hui D; Chung D; Rex TS; Wei Z; Qu G; Zhou S; Zeiss C; Arruda VR; Acland GM; Dell'Osso LF; High KA; Maguire AM; Bennett J
Mol Ther; 2008 Mar; 16(3):458-65. PubMed ID: 18209734
[TBL] [Abstract][Full Text] [Related]
14. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
[TBL] [Abstract][Full Text] [Related]
15. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
Stein L; Roy K; Lei L; Kaushal S
Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
[TBL] [Abstract][Full Text] [Related]
16. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection.
Jacobson SG; Acland GM; Aguirre GD; Aleman TS; Schwartz SB; Cideciyan AV; Zeiss CJ; Komaromy AM; Kaushal S; Roman AJ; Windsor EA; Sumaroka A; Pearce-Kelling SE; Conlon TJ; Chiodo VA; Boye SL; Flotte TR; Maguire AM; Bennett J; Hauswirth WW
Mol Ther; 2006 Jun; 13(6):1074-84. PubMed ID: 16644289
[TBL] [Abstract][Full Text] [Related]
17. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery.
Weber M; Rabinowitz J; Provost N; Conrath H; Folliot S; Briot D; Chérel Y; Chenuaud P; Samulski J; Moullier P; Rolling F
Mol Ther; 2003 Jun; 7(6):774-81. PubMed ID: 12788651
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of doxycycline allows tight control of transgene expression: a key step towards gene therapy of retinal diseases.
Stieger K; Mendes-Madeira A; Meur GL; Weber M; Deschamps JY; Nivard D; Provost N; Moullier P; Rolling F
Gene Ther; 2007 Dec; 14(23):1668-73. PubMed ID: 17914405
[TBL] [Abstract][Full Text] [Related]
19. Long-term expression of melanopsin and channelrhodopsin causes no gross alterations in the dystrophic dog retina.
Ameline B; Tshilenge KT; Weber M; Biget M; Libeau L; Caplette R; Mendes-Madeira A; Provost N; Guihal C; Picaud S; Moullier P; Pichard V; Cronin T; Isiegas C
Gene Ther; 2017 Nov; 24(11):735-741. PubMed ID: 28880021
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis.
Pang JJ; Chang B; Kumar A; Nusinowitz S; Noorwez SM; Li J; Rani A; Foster TC; Chiodo VA; Doyle T; Li H; Malhotra R; Teusner JT; McDowell JH; Min SH; Li Q; Kaushal S; Hauswirth WW
Mol Ther; 2006 Mar; 13(3):565-72. PubMed ID: 16223604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
